

Supplemental Information:

Specific Inclusions and Exclusion Criteria: Patients with a history of basal cell skin carcinoma and carcinoma-in-situ of the cervix malignancies within 5 years of study entry were eligible. Patients with asymptomatic brain metastases who received radiation, chemoT, and/or surgical resection were eligible. Patients with recurrent pleural effusion or ascites requiring drainage not more frequently than every 4 weeks were eligible. Women with negative pregnancy test, prior hysterectomy, tubal ligation, or postmenopausal (age >55 years with amenorrhea for >1 year or age <55 years with amenorrhea for 2 years and follicle-stimulating hormone level within postmenopausal range) were eligible.

Exclusion Criteria: No serious medical or psychiatric illness which prevented informed consent. No intensive treatment, prior hormonal therapy, treatment with prior biological agents, taxanes, anthracyclines, other chemotherapeutic, or radiation of axial skeleton is permitted up to 4 weeks prior to apheresis. Patients were ineligible if they had: history of another malignancy within 5 years; history of a recent (<1 year) myocardial infarction (MI) or past MI (> 1 year) with current angina/coronary symptoms requiring medications, evidence of congestive heart failure requiring management, or evidence of depressed LVEF< 45% by MUGA or ECHO.

Table S1. Side Effects, Incidence, and Grade					
Reaction	# Patients Affected (% of patients, n=32)	Total # of Episodes by Grade			
		1	2	3	4
Ascites	1 (3%)	2	1		
Chills	30 (94%)	19	63		
Creatinine	1 (3%)		1		
Diarrhea	2 (7%)	2			
Dyspnea	4 (14%)	2	1	2	
Fatigue	31 (97%)	92			
Fever	19 (59%)	19	19		
Headache	22 (69%)	38	7		
Hypertension	3 (9%)	2	2		
Hypoglycemia	1 (3%)		1		
Hypotension	14 (44%)	3	20		
Hypoxia	2 (7%)	1	1		
Metabolic/Laboratory	1 (3%)		1	1	
Muscle weakness	1 (3%)		1		
Nausea	20 (63%)	38	2		
Pain	4 (13%)	5			
Somnolence	1 (3%)		1	1	
Tachycardia	2 (6%)	2			
Vomiting	11 (34%)	13	1	1	

Table S2. Median OS and TTP						
Group	OS From Enrollment			OS From 1 st Infusion		
	All	HR+	TNBC	All	HR+	TNBC
Combined	17.0	19.0	15.1	13.1	15.2	12.3
ChemoS	18.8	20.5	15.1	14.6	16.5	12.3
ChemoR	11.6	11.6	13.6	8.6	8.6	10.6
Group	TTP from Enrollment			TTP from 1 st Infusion		
	All	HR	TNBC	All	HR+	TNBC
Combined	6.2	2.9	5.8	2.7	2.5	1.4
ChemoS	6.4	2.9	6.8	3.2	3.1	3.2
ChemoR	5.6	2.6	4.75	1.7	1.3	1.7

	HR (n=24)		TNBC (n=8)		All (n=32)	
Median Age (range)	51 (29-73)		55 (28-75)		51 (28-75)	
Prior systemic Therapy	# Patients (TL)	% Patients in each line	# Patients (Total lines)	% Patients in each line	Total #Patients (Total lines)	% Patients in Each Line
1 Line	6 (6)	25	3 (3)	37.5	9 (9)	28.1
2 Lines	4 (8)	16.6	3 (6)	37.5	7 (14)	21.8
3 lines	2 (6)	8.3	0 (0)	0	2 (6)	6.25
≥4 lines	12 (70)	50	2 (10)	25	14 (80)	43.6
TL	(90)		(19)		(109)	
Mean Lines/Patient* TL Including ChemoT	3.75 [4.75]#		2.38 [3.28]		3.40 [4.40]	

*Mean lines/Patients are number of lines to treat metastatic disease and do not include additional 4 cycles or 4 months of chemoT given prior to immunotherapy; # [] Total lines (TL) including the 4 cycles or 4 months of chemoT given as part of the protocol prior to cell infusions.

PBMC Phenotype	Pre inf# 1		Pre inf# 3		4wk Post inf# 3		Pre Inf # 4		4wk Post inf# 4	
	PD	SD	PD	SD	PD	SD	PD	SD	PD	SD
CD3+	45.7	52.7	54.1	56.4	46.3	54.5	60.3	44.2	39.8	49.0
CD4+	34.7	34.0	35.9	38.4	31.5	29.8	39.5	34.9	24.1	33.6
CD8+	11.2	18.7	18.2	18.0	14.7	24.7	20.8	9.3	15.8	15.5
CD4/CD8	3.7	3.2	4.0	3.7	2.7	1.7	2.5	4.3	1.5	4.0
CD56+	18.7	8.5	17.5	13.4	17.7	2.1	8.5	8.4	8.3	18.2
T_{MEM}(CD4)	21.3	18.9	23.5	17.1	21.2	9.0	28.6	24.4	16.0	23.0
T_{MEM}(CD8)	2.9	4.0	5.0	0.8	3.7	3.7	8.1	5.0	9.1	10.2
Treg	0.9	0.0	0.3	0.0	0.0					1.1
MDSC	0.1	0.0	0.1	0.1	0.1			0.0		0.1

Table S5. Fold Increases in Cytokines/Chemokines

	PreIT (Median)	PostIT (Median)	Fold Change	p Value
IL-2	6	142.5	23.8	0.0001
IL-2R	16.5	178	10.8	0.0005
IL-12	114	184	1.6	0.0001
TNF-α	5	231	46.2	0.0001
IFN-γ	2	29	14.5	0.0001
GM-CSF	2	9	4.5	0.0003
IL-4	9	46	5.1	0.001
IL-10	3	14.25	4.8	0.0001
IL-13	2	16.75	8.4	0.0001
IP-10	244	571.8	2.3	0.006
MIG	7	40	5.7	0.0003
IL-8	198	790.5	4.0	0.01
MIP-1α	7	175.3	25.0	0.0001
MIP-1β	15.5	168.8	10.9	0.0001